Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Case Report: Radical nephroureterectomy after toripalimab plus disitamab vedotin in biomarker-non-enriched upper tract urothelial carcinoma. Local targets link to admitted publications; unresolved targets remain external evidence.
European association of urology guidelines on upper urinary tract urothelial carcinoma: summary of the 2025 update
10.1016/j.eururo.2025.02.023 · 2025 · External reference
Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA/SUO guideline
10.1097/ju.0000000000003480 · 2023 · External reference
Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study
10.1016/j.annonc.2024.12.002 · 2025 · External reference
Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study
10.1016/j.medj.2025.100637 · 2025 · External reference
Safety, efficacy, and biomarker analysis of toripalimab in patients with previously treated advanced urothelial carcinoma: Results from a multicenter phase II trial POLARIS-03
10.1158/1078-0432.ccr-21-2210 · 2022 · External reference
Impact of histological subtypes/divergent differentiation on clinicopathological and oncological outcomes for patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: A comprehensive updated systematic review and meta-analysis
10.1016/j.euo.2025.03.003 · 2025 · External reference
Diagnostic accuracy of ureteroscopic biopsy in predicting stage and grade at final pathology in upper tract urothelial carcinoma: Systematic review and meta-analysis
10.1016/j.ejso.2020.06.024 · 2020 · External reference
Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: Extended immunohistochemical profiles emphasizing novel markers
10.1038/modpathol.2012.229 · 2013 · External reference
Spatial expression of HER2, NECTIN4, and TROP-2 in muscle-invasive bladder cancer and metastases: Implications for pathological and clinical management
10.1016/j.modpat.2025.100753 · 2025 · External reference
Concordance of PD-L1 expression in matched urothelial bladder cancer specimens
10.1111/his.13710 · 2018 · External reference
Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors
10.1007/s10120-021-01168-7 · 2021 · External reference
Real-world efficacy and safety of disitamab vedotin monotherapy or in combination with PD-1 inhibitors in locally advanced or metastatic upper tract urothelial carcinoma: a multicenter retrospective study
10.3389/fimmu.2025.1699538 · 2025 · External reference
Impact of variant histology on oncological outcomes in upper tract urothelial carcinoma: Results from the ROBUUST Collaborative Group
10.1016/j.clgc.2023.05.011 · 2023 · External reference
The prognostic impact of squamous and glandular differentiation for upper tract urothelial carcinoma patients after radical nephroureterectomy
10.1007/s00345-015-1715-0 · 2016 · External reference
Sarcomatoid carcinoma of the upper urinary tract: Clinical outcome and molecular characterization
10.1016/j.humpath.2008.07.003 · 2009 · External reference
Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma
10.1016/j.urolonc.2021.01.031 · 2021 · External reference
The role of primary tumour site surgery in metastatic UTUC: a systematic review and meta-analysis
10.1111/bju.16836 · 2025 · External reference
